ADCT Announces Q1 2026 Earnings Results
ADCT reported Q1 2026 earnings with net product revenue of $20.0 million for ZYNLONTA, up from $17.4 million. The company saw a reduction in non-GAAP operating expenses by 13% and expects to announce top-line data from the LOTIS-5 Phase III trial before the end of June.
Tickers: $ADCT
Topics: cash position clinical trial updates earnings net loss operating expenses revenue